AAPG · Nasdaq · CIK 0002023311

ASCENTAGE PHARMA GROUP INTERNATIONAL

ASCENTAGE PHARMA GROUP INTERNATIONAL’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 22, 2026. In fiscal 2024 (year ended Dec 31, 2024) it reported revenue of CNY 980.6M and net income of -CNY 405.7M, according to its XBRL data on EDGAR. Its EDGAR record lists 3 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2024
CNY 980.6M
Net income, FY2024
-CNY 405.7M
Form 4 filings on record, past 12 months
3

Company overview

Legal name (as filed)
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ticker
AAPG
SEC Central Index Key (CIK)
0002023311
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
SUZHOU , JIANGSU
State or country of incorporation
Cayman Islands
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Emerging growth company
Position in SEC ticker list
#2216 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from ASCENTAGE PHARMA GROUP INTERNATIONAL’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in CNY; the fiscal year is named for the calendar year in which it ends.

Revenue
CNY 209.7MFY2022CNY 222.0MFY2023CNY 980.6MFY2024
Net income
-CNY 882.9MFY2022-CNY 925.7MFY2023-CNY 405.7MFY2024
AAPG annual results
ItemFY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024
RevenueCNY 209.7MCNY 222.0MCNY 980.6M
Net income-CNY 882.9M-CNY 925.7M-CNY 405.7M
Diluted EPS-CNY 3.35-CNY 3.28-CNY 1.34
Total assets———
Cash and equivalentsCNY 1.3BCNY 1.0BCNY 893.1M

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

AAPG latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Apr 29, 202620-FANNUAL REPORT· period Dec 31, 2025Document · Index
Oct 22, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Oct 22, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about ASCENTAGE PHARMA GROUP INTERNATIONAL, by form type:

6-K ×273 ×54 ×33/A ×3F-3ASR ×120-F ×1
AAPG recent filings
FiledFormWhat it isOriginal
Oct 22, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Oct 22, 2026Document · Index
Oct 21, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Oct 21, 2026Document · Index
Oct 15, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Oct 15, 2026Document · Index
Sep 29, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Sep 28, 2026Document · Index
Sep 17, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Sep 17, 2026Document · Index
Aug 20, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Aug 20, 2026Document · Index
Aug 13, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Aug 13, 2026Document · Index
Aug 5, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Aug 5, 2026Document · Index
Aug 3, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Aug 3, 2026Document · Index
Jul 27, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Jul 27, 2026Document · Index
Jul 20, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Jul 20, 2026Document · Index
Jul 20, 2026F-3ASRREGISTRATION STATEMENTDocument · Index
Jul 13, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Jul 13, 2026Document · Index
Jun 30, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 30, 2026Document · Index
Jun 29, 20263Initial statement of beneficial ownership· period Jun 25, 2026Document · Index
Jun 15, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 15, 2026Document · Index
Jun 12, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 11, 2026Document · Index
Jun 10, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 10, 2026Document · Index
Jun 1, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 1, 2026Document · Index
May 28, 20266-KCURRENT REPORT· period May 28, 2026Document · Index
May 28, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period May 27, 2026Document · Index
May 22, 20264Statement of changes in beneficial ownership (insider trade)· period May 20, 2026Document · Index
May 22, 20264Statement of changes in beneficial ownership (insider trade)· period May 20, 2026Document · Index
May 22, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period May 22, 2026Document · Index
May 13, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period May 13, 2026Document · Index
May 12, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period May 12, 2026Document · Index
May 1, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Apr 30, 2026Document · Index
Apr 29, 202620-FANNUAL REPORT· period Dec 31, 2025Document · Index
Apr 22, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Apr 22, 2026Document · Index
Apr 21, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 20, 2026Document · Index
Apr 21, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Apr 20, 20263/AInitial statement of beneficial ownership· period Mar 18, 2026Document · Index
Apr 20, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Apr 20, 2026Document · Index
Apr 10, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Apr 1, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Apr 1, 2026Document · Index
Mar 26, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Mar 26, 2026Document · Index
Mar 23, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 23, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 23, 20263/AInitial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 23, 20263/AInitial statement of beneficial ownership· period Mar 18, 2026Document · Index

Insider filing activity

3 Form 4 filings appear in ASCENTAGE PHARMA GROUP INTERNATIONAL’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0002023311 and XBRL company facts. ASCENTAGE PHARMA GROUP INTERNATIONAL on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.